Zoetis Inc. (NYSE:ZTS) Shares Sold by Princeton Global Asset Management LLC

Princeton Global Asset Management LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 11.3% in the 4th quarter, Holdings Channel reports. The firm owned 2,927 shares of the company’s stock after selling 374 shares during the period. Princeton Global Asset Management LLC’s holdings in Zoetis were worth $477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis during the 3rd quarter worth about $33,000. Dunhill Financial LLC boosted its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Finally, Quarry LP boosted its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Morgan Stanley dropped their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $215.00.

Zoetis Stock Down 1.1 %

NYSE ZTS opened at $170.81 on Monday. The stock has a market cap of $77.06 billion, a PE ratio of 32.11, a P/E/G ratio of 2.72 and a beta of 0.90. The business has a 50 day moving average price of $169.62 and a two-hundred day moving average price of $179.46. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the business earned $1.36 EPS. The business’s revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.